Salhab A S, James M O, Wang S L, Shiverick K T
Chem Biol Interact. 1987 Mar;61(3):203-14. doi: 10.1016/0009-2797(87)90001-9.
The formation of benzo[a]pyrene (BP)-DNA adducts was studied in vitro in the presence of microsomes prepared from the isolated labyrinth zone of the rat placenta, the hematopoietic erythroblast cells of the fetal liver, the fetal liver, as well as the maternal liver. Pregnant rats received beta-naphthoflavone (beta NF; 15 mg/kg, i.p.) on day 17 gestation. One day later, placentae, fetal and maternal livers were obtained and hematopoietic erythroblast cells were separated from hepatocytes in the fetal livers. The respective microsomal fractions were incubated in the presence of calf thymus DNA, NADPH-regenerating system and [3H]BP (300 microCi) at 37 degrees C for 30 min. Following beta NF pretreatment, the levels of covalent binding (pmol/mg DNA/mg microsomal protein) for maternal liver, fetal liver, placenta and erythroblast cells were: 28.4, 2.4, 0.31 and 3.9, respectively, with the hematopoietic erythroblast cells being the most active among fetal tissue preparations. The extent of transplacental induction compared to control was greatest in the hematopoietic cells (18-fold) followed by fetal liver (16-fold) and labyrinth zone (5-fold). Further experiments characterized the BP-DNA adducts formed by induced microsomes. DNA was isolated, purified and digested sequentially with DNase I, snake venom phosphodiesterase type II and alkaline phosphatase type III. The deoxynucleoside-BP adducts were purified on a Sephadex LH-20 column and then separated on HPLC and the adducts were quantitated radiometrically. Seven distinct adducts were separated on HPLC and named A-G in order of elution. Adduct B was prominent in all preparations (22-55% total radioactivity). The adduct profile and retention time for peak B is similar to that reported for the adduct formed by microsomal activation of 9-hydroxy BP. Peak D constituted a major fraction (19%) in maternal liver profiles in comparison with the three fetal tissue preparations (8%). In subsequent experiments, peak D was shown to be derived from reaction of (+/-)7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE) with DNA. Peak C was unique to erythroblast cell and labyrinth profiles, while peak G was specific for maternal liver and fetal liver profiles. These results demonstrate that fetal liver and its hematopoietic cells are significant sites of BP bioactivation which may contribute to the fetal toxicity of polyaromatic hydrocarbons.
在存在从大鼠胎盘分离的迷路区、胎儿肝脏的造血成红细胞、胎儿肝脏以及母体肝脏制备的微粒体的情况下,对苯并[a]芘(BP)-DNA加合物的形成进行了体外研究。妊娠大鼠在妊娠第17天接受β-萘黄酮(βNF;15mg/kg,腹腔注射)。一天后,获取胎盘、胎儿和母体肝脏,并从胎儿肝脏的肝细胞中分离出造血成红细胞。将各自的微粒体部分在小牛胸腺DNA、NADPH再生系统和[3H]BP(300μCi)存在下于37℃孵育30分钟。经过βNF预处理后,母体肝脏、胎儿肝脏、胎盘和成红细胞的共价结合水平(pmol/mg DNA/mg微粒体蛋白)分别为:28.4、2.4、0.31和3.9,其中造血成红细胞在胎儿组织制剂中活性最高。与对照组相比,跨胎盘诱导程度在造血细胞中最大(18倍),其次是胎儿肝脏(16倍)和迷路区(5倍)。进一步的实验对诱导微粒体形成的BP-DNA加合物进行了表征。分离、纯化DNA,然后依次用DNase I、II型蛇毒磷酸二酯酶和III型碱性磷酸酶消化。脱氧核苷-BP加合物在Sephadex LH-20柱上纯化,然后在HPLC上分离,并用放射性测定法定量加合物。在HPLC上分离出7种不同的加合物,并按洗脱顺序命名为A-G。加合物B在所有制剂中都很突出(占总放射性的22-55%)。峰B的加合物图谱和保留时间与报道的由微粒体激活9-羟基BP形成的加合物相似。与三种胎儿组织制剂(8%)相比,峰D在母体肝脏图谱中占主要部分(19%)。在随后的实验中,峰D被证明源自(±)7β,8α-二羟基-9α,10α-环氧-7,8,9,10-四氢苯并[a]芘(BPDE)与DNA的反应。峰C是成红细胞和迷路图谱所特有的,而峰G是母体肝脏和胎儿肝脏图谱所特有的。这些结果表明,胎儿肝脏及其造血细胞是BP生物活化的重要部位,这可能导致多环芳烃对胎儿的毒性。